Market growth is driven mainly by factors such as increasing R spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput screening market and the availability of government funding & venture capital investments.
Emerging markets and growing applications in life sciences research are also factors expected to provide growth opportunities for players in the HTS market.The global High-Throughput Screening (HTS) Market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950Market Segmentation: -The consumables segment accounted for the largest share of the product & services segment in the high-throughput screening market in 2019.On the basis type ofproduct & service, the high-throughput screening market is broadly segmented into consumables , instruments, services, and software.
In 2019, consumables accounted for the largest share of the high-throughput screening market.
This can primarily be attributed to the wide use of reagents & assay kits in HTS techniques, increasing pharmaceutical R, and rising government funding for life sciences research.The drug discovery segment accounted for the largest share of the application segment in the high-throughput screening market in 2019.
Based on application, the high-throughput screening market is categorized into four segments—drug discovery, biochemical screening, life sciences, and other applications.
The drug discovery application segment accounted for the largest share of the high-throughput screening market in 2019.
Market growth is driven mainly by factors such as increasing R spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput screening market and the availability of government funding & venture capital investments.
Emerging markets and growing applications in life sciences research are also factors expected to provide growth opportunities for players in the HTS market.The global High-Throughput Screening (HTS) Market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950Market Segmentation: -The consumables segment accounted for the largest share of the product & services segment in the high-throughput screening market in 2019.On the basis type ofproduct & service, the high-throughput screening market is broadly segmented into consumables , instruments, services, and software.
In 2019, consumables accounted for the largest share of the high-throughput screening market.
This can primarily be attributed to the wide use of reagents & assay kits in HTS techniques, increasing pharmaceutical R, and rising government funding for life sciences research.The drug discovery segment accounted for the largest share of the application segment in the high-throughput screening market in 2019.
Based on application, the high-throughput screening market is categorized into four segments—drug discovery, biochemical screening, life sciences, and other applications.
The drug discovery application segment accounted for the largest share of the high-throughput screening market in 2019.
Market growth is driven mainly by factors such as increasing R spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput screening market and the availability of government funding & venture capital investments.
Emerging markets and growing applications in life sciences research are also factors expected to provide growth opportunities for players in the HTS market.The global High-Throughput Screening (HTS) Market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950Market Segmentation: -The consumables segment accounted for the largest share of the product & services segment in the high-throughput screening market in 2019.On the basis type ofproduct & service, the high-throughput screening market is broadly segmented into consumables , instruments, services, and software.
In 2019, consumables accounted for the largest share of the high-throughput screening market.
This can primarily be attributed to the wide use of reagents & assay kits in HTS techniques, increasing pharmaceutical R, and rising government funding for life sciences research.The drug discovery segment accounted for the largest share of the application segment in the high-throughput screening market in 2019.
Based on application, the high-throughput screening market is categorized into four segments—drug discovery, biochemical screening, life sciences, and other applications.
The drug discovery application segment accounted for the largest share of the high-throughput screening market in 2019.
Rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, and the rising demand for external quality assessment support are the key factor driving market growth.The Molecular Quality Controls Market  is expected to grow from USD 132 million in 2018 to USD 237 million by 2024, at a CAGR of 10.2% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523Market Segmentation:-Based on product type, the molecular controls market is divided into two major segments—instrument-specific controls and independent controls.
The independent controls segment accounted for a larger share of the molecular controls market in 2018.
The large share of this segment is attributed to the increasing use of third-party independent quality controls due to their benefits such as longer shelf-life and flexible use across different reagent lots, which help reduce the cost of operations.By analyte type, the molecular controls market is segmented into single-analyte controls and multi-analyte controls.
Single-analyte controls dominated the molecular controls market in 2018 primarily due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity.Recent Developments:-In 2018, Seracare partnered with AccuRef Diagnostics, a division of Applied StemCell, Inc (US), to market and sell Accuref’s broad portfolio of CRISPR-engineered cell line reference materials.In 2018, Thermo Fisher Scientific partnered with West China Hospital of Sichuan University (China) to establish training centers for standardized pathology quality control, standardized pathologic diagnosticians, and advanced laboratories.In 2017, Bio-Rad launched Amplichek STI—a Multi-analyte Quality ControlIn 2018, Microbiologics launched 8 quality control products such as, Human Papillomavirus (HPV) Control Panel, Vaginal Control Panel, Vaginal Verification Panel, Blood Culture (BCID) Control Panel, Enteric Viral Control Panel and others.Regional Analysis:-North America held the largest share of the market in 2018, Asia Pacific is estimated to grow at the highest CAGR during the forecast period.Request for Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523  Top Key Players:-The prominent players in the molecular quality controls market are SeraCare Life Sciences Inc. (US), ZeptoMetrix Corporation (US), Bio-Rad Laboratories Inc. (US), Microbiologics Inc. (US), and Thermo Fisher Scientific (US).
Rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, and the rising demand for external quality assessment support are the key factor driving market growth.The Molecular Quality Controls Market  is expected to grow from USD 132 million in 2018 to USD 237 million by 2024, at a CAGR of 10.2% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523Market Segmentation:-Based on product type, the molecular controls market is divided into two major segments—instrument-specific controls and independent controls.
The independent controls segment accounted for a larger share of the molecular controls market in 2018.
The large share of this segment is attributed to the increasing use of third-party independent quality controls due to their benefits such as longer shelf-life and flexible use across different reagent lots, which help reduce the cost of operations.By analyte type, the molecular controls market is segmented into single-analyte controls and multi-analyte controls.
Single-analyte controls dominated the molecular controls market in 2018 primarily due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity.Recent Developments:-In 2018, Seracare partnered with AccuRef Diagnostics, a division of Applied StemCell, Inc (US), to market and sell Accuref’s broad portfolio of CRISPR-engineered cell line reference materials.In 2018, Thermo Fisher Scientific partnered with West China Hospital of Sichuan University (China) to establish training centers for standardized pathology quality control, standardized pathologic diagnosticians, and advanced laboratories.In 2017, Bio-Rad launched Amplichek STI—a Multi-analyte Quality ControlIn 2018, Microbiologics launched 8 quality control products such as, Human Papillomavirus (HPV) Control Panel, Vaginal Control Panel, Vaginal Verification Panel, Blood Culture (BCID) Control Panel, Enteric Viral Control Panel and others.Regional Analysis:-North America held the largest share of the market in 2018, Asia Pacific is estimated to grow at the highest CAGR during the forecast period.Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523  Top Key Players:-The prominent players in the molecular quality controls market are SeraCare Life Sciences Inc. (US), ZeptoMetrix Corporation (US), Bio-Rad Laboratories Inc. (US), Microbiologics Inc. (US), and Thermo Fisher Scientific (US).Â
Rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, and the rising demand for external quality assessment support are the key factor driving market growth.The Molecular Quality Controls Market  is expected to grow from USD 132 million in 2018 to USD 237 million by 2024, at a CAGR of 10.2% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523Market Segmentation:-Based on product type, the molecular controls market is divided into two major segments—instrument-specific controls and independent controls.
The independent controls segment accounted for a larger share of the molecular controls market in 2018.
The large share of this segment is attributed to the increasing use of third-party independent quality controls due to their benefits such as longer shelf-life and flexible use across different reagent lots, which help reduce the cost of operations.By analyte type, the molecular controls market is segmented into single-analyte controls and multi-analyte controls.
Single-analyte controls dominated the molecular controls market in 2018 primarily due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity.Recent Developments:-In 2018, Seracare partnered with AccuRef Diagnostics, a division of Applied StemCell, Inc (US), to market and sell Accuref’s broad portfolio of CRISPR-engineered cell line reference materials.In 2018, Thermo Fisher Scientific partnered with West China Hospital of Sichuan University (China) to establish training centers for standardized pathology quality control, standardized pathologic diagnosticians, and advanced laboratories.In 2017, Bio-Rad launched Amplichek STI—a Multi-analyte Quality ControlIn 2018, Microbiologics launched 8 quality control products such as, Human Papillomavirus (HPV) Control Panel, Vaginal Control Panel, Vaginal Verification Panel, Blood Culture (BCID) Control Panel, Enteric Viral Control Panel and others.Regional Analysis:-North America held the largest share of the market in 2018, Asia Pacific is estimated to grow at the highest CAGR during the forecast period.Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523  Top Key Players:-The prominent players in the molecular quality controls market are SeraCare Life Sciences Inc. (US), ZeptoMetrix Corporation (US), Bio-Rad Laboratories Inc. (US), Microbiologics Inc. (US), and Thermo Fisher Scientific (US).Â
Rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, and the rising demand for external quality assessment support are the key factor driving market growth.The Molecular Quality Controls Market  is expected to grow from USD 132 million in 2018 to USD 237 million by 2024, at a CAGR of 10.2% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523Market Segmentation:-Based on product type, the molecular controls market is divided into two major segments—instrument-specific controls and independent controls.
The independent controls segment accounted for a larger share of the molecular controls market in 2018.
The large share of this segment is attributed to the increasing use of third-party independent quality controls due to their benefits such as longer shelf-life and flexible use across different reagent lots, which help reduce the cost of operations.By analyte type, the molecular controls market is segmented into single-analyte controls and multi-analyte controls.
Single-analyte controls dominated the molecular controls market in 2018 primarily due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity.Recent Developments:-In 2018, Seracare partnered with AccuRef Diagnostics, a division of Applied StemCell, Inc (US), to market and sell Accuref’s broad portfolio of CRISPR-engineered cell line reference materials.In 2018, Thermo Fisher Scientific partnered with West China Hospital of Sichuan University (China) to establish training centers for standardized pathology quality control, standardized pathologic diagnosticians, and advanced laboratories.In 2017, Bio-Rad launched Amplichek STI—a Multi-analyte Quality ControlIn 2018, Microbiologics launched 8 quality control products such as, Human Papillomavirus (HPV) Control Panel, Vaginal Control Panel, Vaginal Verification Panel, Blood Culture (BCID) Control Panel, Enteric Viral Control Panel and others.Regional Analysis:-North America held the largest share of the market in 2018, Asia Pacific is estimated to grow at the highest CAGR during the forecast period.Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523  Top Key Players:-The prominent players in the molecular quality controls market are SeraCare Life Sciences Inc. (US), ZeptoMetrix Corporation (US), Bio-Rad Laboratories Inc. (US), Microbiologics Inc. (US), and Thermo Fisher Scientific (US).
Rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, and the rising demand for external quality assessment support are the key factor driving market growth.The Molecular Quality Controls Market  is expected to grow from USD 132 million in 2018 to USD 237 million by 2024, at a CAGR of 10.2% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523Market Segmentation:-Based on product type, the molecular controls market is divided into two major segments—instrument-specific controls and independent controls.
The independent controls segment accounted for a larger share of the molecular controls market in 2018.
The large share of this segment is attributed to the increasing use of third-party independent quality controls due to their benefits such as longer shelf-life and flexible use across different reagent lots, which help reduce the cost of operations.By analyte type, the molecular controls market is segmented into single-analyte controls and multi-analyte controls.
Single-analyte controls dominated the molecular controls market in 2018 primarily due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity.Recent Developments:-In 2018, Seracare partnered with AccuRef Diagnostics, a division of Applied StemCell, Inc (US), to market and sell Accuref’s broad portfolio of CRISPR-engineered cell line reference materials.In 2018, Thermo Fisher Scientific partnered with West China Hospital of Sichuan University (China) to establish training centers for standardized pathology quality control, standardized pathologic diagnosticians, and advanced laboratories.In 2017, Bio-Rad launched Amplichek STI—a Multi-analyte Quality ControlIn 2018, Microbiologics launched 8 quality control products such as, Human Papillomavirus (HPV) Control Panel, Vaginal Control Panel, Vaginal Verification Panel, Blood Culture (BCID) Control Panel, Enteric Viral Control Panel and others.Regional Analysis:-North America held the largest share of the market in 2018, Asia Pacific is estimated to grow at the highest CAGR during the forecast period.Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523  Top Key Players:-The prominent players in the molecular quality controls market are SeraCare Life Sciences Inc. (US), ZeptoMetrix Corporation (US), Bio-Rad Laboratories Inc. (US), Microbiologics Inc. (US), and Thermo Fisher Scientific (US).
Market growth is driven mainly by factors such as increasing R spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput screening market and the availability of government funding & venture capital investments.
Emerging markets and growing applications in life sciences research are also factors expected to provide growth opportunities for players in the HTS market.The global High-Throughput Screening (HTS) Market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950Market Segmentation: -The consumables segment accounted for the largest share of the product & services segment in the high-throughput screening market in 2019.On the basis type ofproduct & service, the high-throughput screening market is broadly segmented into consumables , instruments, services, and software.
In 2019, consumables accounted for the largest share of the high-throughput screening market.
This can primarily be attributed to the wide use of reagents & assay kits in HTS techniques, increasing pharmaceutical R, and rising government funding for life sciences research.The drug discovery segment accounted for the largest share of the application segment in the high-throughput screening market in 2019.
Based on application, the high-throughput screening market is categorized into four segments—drug discovery, biochemical screening, life sciences, and other applications.
The drug discovery application segment accounted for the largest share of the high-throughput screening market in 2019.
Market growth is driven mainly by factors such as increasing R spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput screening market and the availability of government funding & venture capital investments.
Emerging markets and growing applications in life sciences research are also factors expected to provide growth opportunities for players in the HTS market.The global High-Throughput Screening (HTS) Market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950Market Segmentation: -The consumables segment accounted for the largest share of the product & services segment in the high-throughput screening market in 2019.On the basis type ofproduct & service, the high-throughput screening market is broadly segmented into consumables , instruments, services, and software.
In 2019, consumables accounted for the largest share of the high-throughput screening market.
This can primarily be attributed to the wide use of reagents & assay kits in HTS techniques, increasing pharmaceutical R, and rising government funding for life sciences research.The drug discovery segment accounted for the largest share of the application segment in the high-throughput screening market in 2019.
Based on application, the high-throughput screening market is categorized into four segments—drug discovery, biochemical screening, life sciences, and other applications.
The drug discovery application segment accounted for the largest share of the high-throughput screening market in 2019.
Rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, and the rising demand for external quality assessment support are the key factor driving market growth.The Molecular Quality Controls Market  is expected to grow from USD 132 million in 2018 to USD 237 million by 2024, at a CAGR of 10.2% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523Market Segmentation:-Based on product type, the molecular controls market is divided into two major segments—instrument-specific controls and independent controls.
The independent controls segment accounted for a larger share of the molecular controls market in 2018.
The large share of this segment is attributed to the increasing use of third-party independent quality controls due to their benefits such as longer shelf-life and flexible use across different reagent lots, which help reduce the cost of operations.By analyte type, the molecular controls market is segmented into single-analyte controls and multi-analyte controls.
Single-analyte controls dominated the molecular controls market in 2018 primarily due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity.Recent Developments:-In 2018, Seracare partnered with AccuRef Diagnostics, a division of Applied StemCell, Inc (US), to market and sell Accuref’s broad portfolio of CRISPR-engineered cell line reference materials.In 2018, Thermo Fisher Scientific partnered with West China Hospital of Sichuan University (China) to establish training centers for standardized pathology quality control, standardized pathologic diagnosticians, and advanced laboratories.In 2017, Bio-Rad launched Amplichek STI—a Multi-analyte Quality ControlIn 2018, Microbiologics launched 8 quality control products such as, Human Papillomavirus (HPV) Control Panel, Vaginal Control Panel, Vaginal Verification Panel, Blood Culture (BCID) Control Panel, Enteric Viral Control Panel and others.Regional Analysis:-North America held the largest share of the market in 2018, Asia Pacific is estimated to grow at the highest CAGR during the forecast period.Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523  Top Key Players:-The prominent players in the molecular quality controls market are SeraCare Life Sciences Inc. (US), ZeptoMetrix Corporation (US), Bio-Rad Laboratories Inc. (US), Microbiologics Inc. (US), and Thermo Fisher Scientific (US).Â
Rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, and the rising demand for external quality assessment support are the key factor driving market growth.The Molecular Quality Controls Market  is expected to grow from USD 132 million in 2018 to USD 237 million by 2024, at a CAGR of 10.2% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523Market Segmentation:-Based on product type, the molecular controls market is divided into two major segments—instrument-specific controls and independent controls.
The independent controls segment accounted for a larger share of the molecular controls market in 2018.
The large share of this segment is attributed to the increasing use of third-party independent quality controls due to their benefits such as longer shelf-life and flexible use across different reagent lots, which help reduce the cost of operations.By analyte type, the molecular controls market is segmented into single-analyte controls and multi-analyte controls.
Single-analyte controls dominated the molecular controls market in 2018 primarily due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity.Recent Developments:-In 2018, Seracare partnered with AccuRef Diagnostics, a division of Applied StemCell, Inc (US), to market and sell Accuref’s broad portfolio of CRISPR-engineered cell line reference materials.In 2018, Thermo Fisher Scientific partnered with West China Hospital of Sichuan University (China) to establish training centers for standardized pathology quality control, standardized pathologic diagnosticians, and advanced laboratories.In 2017, Bio-Rad launched Amplichek STI—a Multi-analyte Quality ControlIn 2018, Microbiologics launched 8 quality control products such as, Human Papillomavirus (HPV) Control Panel, Vaginal Control Panel, Vaginal Verification Panel, Blood Culture (BCID) Control Panel, Enteric Viral Control Panel and others.Regional Analysis:-North America held the largest share of the market in 2018, Asia Pacific is estimated to grow at the highest CAGR during the forecast period.Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523  Top Key Players:-The prominent players in the molecular quality controls market are SeraCare Life Sciences Inc. (US), ZeptoMetrix Corporation (US), Bio-Rad Laboratories Inc. (US), Microbiologics Inc. (US), and Thermo Fisher Scientific (US).
Market growth is driven mainly by factors such as increasing R spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput screening market and the availability of government funding & venture capital investments.
Emerging markets and growing applications in life sciences research are also factors expected to provide growth opportunities for players in the HTS market.The global High-Throughput Screening (HTS) Market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950Market Segmentation: -The consumables segment accounted for the largest share of the product & services segment in the high-throughput screening market in 2019.On the basis type ofproduct & service, the high-throughput screening market is broadly segmented into consumables , instruments, services, and software.
In 2019, consumables accounted for the largest share of the high-throughput screening market.
This can primarily be attributed to the wide use of reagents & assay kits in HTS techniques, increasing pharmaceutical R, and rising government funding for life sciences research.The drug discovery segment accounted for the largest share of the application segment in the high-throughput screening market in 2019.
Based on application, the high-throughput screening market is categorized into four segments—drug discovery, biochemical screening, life sciences, and other applications.
The drug discovery application segment accounted for the largest share of the high-throughput screening market in 2019.
Rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, and the rising demand for external quality assessment support are the key factor driving market growth.The Molecular Quality Controls Market  is expected to grow from USD 132 million in 2018 to USD 237 million by 2024, at a CAGR of 10.2% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523Market Segmentation:-Based on product type, the molecular controls market is divided into two major segments—instrument-specific controls and independent controls.
The independent controls segment accounted for a larger share of the molecular controls market in 2018.
The large share of this segment is attributed to the increasing use of third-party independent quality controls due to their benefits such as longer shelf-life and flexible use across different reagent lots, which help reduce the cost of operations.By analyte type, the molecular controls market is segmented into single-analyte controls and multi-analyte controls.
Single-analyte controls dominated the molecular controls market in 2018 primarily due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity.Recent Developments:-In 2018, Seracare partnered with AccuRef Diagnostics, a division of Applied StemCell, Inc (US), to market and sell Accuref’s broad portfolio of CRISPR-engineered cell line reference materials.In 2018, Thermo Fisher Scientific partnered with West China Hospital of Sichuan University (China) to establish training centers for standardized pathology quality control, standardized pathologic diagnosticians, and advanced laboratories.In 2017, Bio-Rad launched Amplichek STI—a Multi-analyte Quality ControlIn 2018, Microbiologics launched 8 quality control products such as, Human Papillomavirus (HPV) Control Panel, Vaginal Control Panel, Vaginal Verification Panel, Blood Culture (BCID) Control Panel, Enteric Viral Control Panel and others.Regional Analysis:-North America held the largest share of the market in 2018, Asia Pacific is estimated to grow at the highest CAGR during the forecast period.Request for Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523  Top Key Players:-The prominent players in the molecular quality controls market are SeraCare Life Sciences Inc. (US), ZeptoMetrix Corporation (US), Bio-Rad Laboratories Inc. (US), Microbiologics Inc. (US), and Thermo Fisher Scientific (US).
Rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, and the rising demand for external quality assessment support are the key factor driving market growth.The Molecular Quality Controls Market  is expected to grow from USD 132 million in 2018 to USD 237 million by 2024, at a CAGR of 10.2% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523Market Segmentation:-Based on product type, the molecular controls market is divided into two major segments—instrument-specific controls and independent controls.
The independent controls segment accounted for a larger share of the molecular controls market in 2018.
The large share of this segment is attributed to the increasing use of third-party independent quality controls due to their benefits such as longer shelf-life and flexible use across different reagent lots, which help reduce the cost of operations.By analyte type, the molecular controls market is segmented into single-analyte controls and multi-analyte controls.
Single-analyte controls dominated the molecular controls market in 2018 primarily due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity.Recent Developments:-In 2018, Seracare partnered with AccuRef Diagnostics, a division of Applied StemCell, Inc (US), to market and sell Accuref’s broad portfolio of CRISPR-engineered cell line reference materials.In 2018, Thermo Fisher Scientific partnered with West China Hospital of Sichuan University (China) to establish training centers for standardized pathology quality control, standardized pathologic diagnosticians, and advanced laboratories.In 2017, Bio-Rad launched Amplichek STI—a Multi-analyte Quality ControlIn 2018, Microbiologics launched 8 quality control products such as, Human Papillomavirus (HPV) Control Panel, Vaginal Control Panel, Vaginal Verification Panel, Blood Culture (BCID) Control Panel, Enteric Viral Control Panel and others.Regional Analysis:-North America held the largest share of the market in 2018, Asia Pacific is estimated to grow at the highest CAGR during the forecast period.Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523  Top Key Players:-The prominent players in the molecular quality controls market are SeraCare Life Sciences Inc. (US), ZeptoMetrix Corporation (US), Bio-Rad Laboratories Inc. (US), Microbiologics Inc. (US), and Thermo Fisher Scientific (US).Â
Rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, and the rising demand for external quality assessment support are the key factor driving market growth.The Molecular Quality Controls Market  is expected to grow from USD 132 million in 2018 to USD 237 million by 2024, at a CAGR of 10.2% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523Market Segmentation:-Based on product type, the molecular controls market is divided into two major segments—instrument-specific controls and independent controls.
The independent controls segment accounted for a larger share of the molecular controls market in 2018.
The large share of this segment is attributed to the increasing use of third-party independent quality controls due to their benefits such as longer shelf-life and flexible use across different reagent lots, which help reduce the cost of operations.By analyte type, the molecular controls market is segmented into single-analyte controls and multi-analyte controls.
Single-analyte controls dominated the molecular controls market in 2018 primarily due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity.Recent Developments:-In 2018, Seracare partnered with AccuRef Diagnostics, a division of Applied StemCell, Inc (US), to market and sell Accuref’s broad portfolio of CRISPR-engineered cell line reference materials.In 2018, Thermo Fisher Scientific partnered with West China Hospital of Sichuan University (China) to establish training centers for standardized pathology quality control, standardized pathologic diagnosticians, and advanced laboratories.In 2017, Bio-Rad launched Amplichek STI—a Multi-analyte Quality ControlIn 2018, Microbiologics launched 8 quality control products such as, Human Papillomavirus (HPV) Control Panel, Vaginal Control Panel, Vaginal Verification Panel, Blood Culture (BCID) Control Panel, Enteric Viral Control Panel and others.Regional Analysis:-North America held the largest share of the market in 2018, Asia Pacific is estimated to grow at the highest CAGR during the forecast period.Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523  Top Key Players:-The prominent players in the molecular quality controls market are SeraCare Life Sciences Inc. (US), ZeptoMetrix Corporation (US), Bio-Rad Laboratories Inc. (US), Microbiologics Inc. (US), and Thermo Fisher Scientific (US).